

First Hit

L2: Entry 10 of 19

File: DWPI

Mar 9, 1994

DERWENT-ACC-NO: 1994-076533

DERWENT-WEEK: 199948

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Compsn. contg. 5-methoxy-psoralen for optical treatment of psoriasis - and other dermatoses e.g. para-psoriasis, vitiligo an atopic eczema, contains natural citrus essence.

INVENTOR: GOUPIL, J J; GOUPIL, J

PATENT-ASSIGNEE: GOUPIL J J (GOUPI), GOUPIL J (GOUPI)

PRIORITY-DATA: 1992FR-0010523 (September 3, 1992)

Search Selected Search ALL Clear

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<input type="checkbox"/> EP 586282 A1	March 9, 1994	F	004	A61K031/37
<input type="checkbox"/> US 5962512 A	October 5, 1999		000	A61K031/35
<input type="checkbox"/> AU 9346015 A	March 10, 1994		000	A61K031/365
<input type="checkbox"/> FR 2695036 A1	March 4, 1994		007	A61K009/00

DESIGNATED-STATES: AT BE CH DE DK ES GB GR IE IT LI LU MC NL PT SE

CITED-DOCUMENTS:EP 197856; FR 2360301 ; FR 2406444 ; FR 2524801

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
EP 586282A1	August 23, 1993	1993EP-0402084	
US 5962512A	August 25, 1993	1993US-0126581	Cont of
US 5962512A	September 8, 1995	1995US-0525952	
AU 9346015A	August 31, 1993	1993AU-0046015	
FR 2695036A1	September 3, 1992	1992FR-0010523	

INT-CL (IPC): A61K 9/00; A61K 31/35; A61K 31/365; A61K 31/37; A61K 47/44

ABSTRACTED-PUB-NO: EP 586282A

BASIC-ABSTRACT:

Compsn. for optical admin. comprises 5-methoxypsoralen (5-MOP) at 60-100 ppm., pref. pref. 65-95 ppm, in an oily formula.

USE/ADVANTAGE - Use of the compsn. to treat psoriasis and other dermatoses e.g.

parapsoriasis, vitiligo and atopic eczema, is claimed. The compsn. is partic. applicable to psoriasis of limited extent or to plaques which are resistant to oral treatment. The compsn. is applied 30-60 mins. before irradiation with UVA at 1-4 joules/cm² (according to skin type) increasing during later sessions but not exceeding 8 joules/cm². Treatment is 3 times per week for 4-6 weeks. Oral use of 5-MOP is known (FR2406444). Some inconveniences of oral treatment are avoided, Combination of oral and topical treatments reduces the number of sessions of puva-therapy by about 25.%.

ABSTRACTED-PUB-NO: US 5962512A

EQUIVALENT-ABSTRACTS:

Compsn. for optical admin. comprises 5-methoxysoralen (5-MOP) at 60-100 ppm., pref. 65-95 ppm, in an oily formula.

USE/ADVANTAGE - Use of the compsn. to treat psoriasis and other dermatoses e.g. parapsoriasis, vitiligo and atopic eczema, is claimed. The compsn. is partic. applicable to psoriasis of limited extent or to plaques which are resistant to oral treatment. The compsn. is applied 30-60 mins. before irradiation with UVA at 1-4 joules/cm² (according to skin type) increasing during later sessions but not exceeding 8 joules/cm². Treatment is 3 times per week for 4-6 weeks. Oral use of 5-MOP is known (FR2406444). Some inconveniences of oral treatment are avoided, Combination of oral and topical treatments reduces the number of sessions of puva-therapy by about 25.%.

CHOSEN-DRAWING: Dwg.0/0

DERWENT-CLASS: B05

CPI-CODES: B04-B01C1; B06-A03; B10-F02; B10-G02; B14-N17;